Research and Development of Novel Anti-thrombotic Agents. Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists.

DOI Web Site PubMed 1 Citations 28 References
  • KONDO Kazunao
    Department of Pharmacology, Hamamatsu University School of Medicine

Bibliographic Information

Other Title
  • 抗血栓薬の現状と新薬開発　　ＧＰ　ＩＩｂ‐ＩＩＩａきっ抗薬の現状と新薬開発
  • GP IIb IIIa キッコウヤク ノ ゲンジョウ ト シンヤク カイハツ
  • 抗血栓薬の現状と新薬開発

Search this article

Abstract

Glycoprotein IIb/IIIa receptors play an important role in platelet aggregation by binding fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases including acute coronary syndrome. These drugs are of four main types: [1] monoclonal antibody, [2] synthetized peptide, [3] non-peptide, and [4] oral antagonist. Since these drugs inhibit the final step in platelet aggregation, i.e., binding of fibrinogen to the platelet membrane, they were expected to 1) have high specificity for inhibiting platelet aggregation, 2) inhibit any kind of aggregation regardless of stimulation, 3) have high potency in aggregation suppression. As a result of large clinical trials, however, monoclonal antibody alone was revealed to be effective, but non-peptide and oral antagonists were ineffective. The possible mechanisms that lead to such inefficiency are: 1) difference in binding duration to platelets, 2) concomitant suppression of other adhesion molecules beside IIb IIIa, 3) difference in binding site in the receptor and presence of a partial agonist effect, 4) aggregation promotion or induction of apoptosis via caspase-3 activation, 5) modified aggregation by gene polymorphism. New findings on platelet physiology through studying ways to overcome the above problems will lead to the development of new drugs and treatment.

Journal

Citations (1)*help

See more

References(28)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top